Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Breast Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 162 articles:
HTML format
Text format



Single Articles


    March 2020
  1. PALUCH-SHIMON S, Cardoso F, Partridge AH, Abulkhair O, et al
    ESO-ESMO 4(rd) International Consensus Guidelines for Breast Cancer in Young Women (BCY4).
    Ann Oncol. 2020 Mar 18. pii: S0923-7534(20)36363.
    PubMed     Text format     Abstract available


  2. GRELLETY T, Peyraud F, Sevenet N, Tredan O, et al
    Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
    Ann Oncol. 2020 Mar 17. pii: S0923-7534(20)36362.
    PubMed     Text format    


  3. VAN DONGEN M, Kok M
    Mise en place: towards neoadjuvant chemo-immunotherapy for early triple-negative breast cancer.
    Ann Oncol. 2020 Mar 11. pii: S0923-7534(20)36075.
    PubMed     Text format    


  4. MURPHY N, Knuppel A, Papadimitriou N, Martin RM, et al
    Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with approximately 430 000 women.
    Ann Oncol. 2020 Mar 9. pii: S0923-7534(20)36019.
    PubMed     Text format     Abstract available


  5. MAVROUDIS D, Saloustros E, Malamos N, Kakolyris S, et al
    Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volu
    Ann Oncol. 2020;31:444-445.
    PubMed     Text format    


  6. MOSS J, Zick A, Grinshpun A, Carmon E, et al
    Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer.
    Ann Oncol. 2020;31:395-403.
    PubMed     Text format     Abstract available


  7. BARROSO-SOUSA R, Jain E, Cohen O, Kim D, et al
    Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Ann Oncol. 2020;31:387-394.
    PubMed     Text format     Abstract available


  8. MOSELE F, Stefanovska B, Lusque A, Tran Dien A, et al
    Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Ann Oncol. 2020;31:377-386.
    PubMed     Text format     Abstract available


    February 2020
  9. BJELIC-RADISIC V, Cardoso F, Cameron D, Brain E, et al
    Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283-288.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36026.
    PubMed     Text format    


  10. ADAMS S, Dieras V, Barrios CH, Winer EP, et al
    Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36038.
    PubMed     Text format     Abstract available


  11. GRYNBERG M, Mayeur Le Bras A, Hesters L, Gallot V, et al
    First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer.
    Ann Oncol. 2020 Feb 12. pii: S0923-7534(20)35923.
    PubMed     Text format    


  12. BJELIC-RADISIC V, Cardoso F, Cameron D, Brain E, et al
    An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45.
    Ann Oncol. 2020;31:283-288.
    PubMed     Text format     Abstract available


    January 2020
  13. PARK YH, Senkus-Konefka E, Im SA, Pentheroudakis G, et al
    Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
    Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35929.
    PubMed     Text format     Abstract available


  14. HEIL J, Kuerer HM, Pfob A, Rauch G, et al
    Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.
    Ann Oncol. 2020;31:61-71.
    PubMed     Text format     Abstract available


    December 2019
  15. BRANDAO M, Caparica R, Eiger D, de Azambuja E, et al
    Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
    Ann Oncol. 2019;30.
    PubMed     Text format     Abstract available


  16. VERRET B, Cortes J, Bachelot T, Andre F, et al
    Efficacy of PI3K inhibitors in advanced breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Text format     Abstract available


  17. VASAN N, Toska E, Scaltriti M
    Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Text format     Abstract available


  18. VASAN N, Toska E, Scaltriti M
    Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Ann Oncol. 2019;30 Suppl 10:x3-x11.
    PubMed     Text format     Abstract available


  19. BRANDAO M, Caparica R, Eiger D, de Azambuja E, et al
    Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
    Ann Oncol. 2019;30 Suppl 10:x27-x42.
    PubMed     Text format     Abstract available


  20. VERRET B, Cortes J, Bachelot T, Andre F, et al
    Efficacy of PI3K inhibitors in advanced breast cancer.
    Ann Oncol. 2019;30 Suppl 10:x12-x20.
    PubMed     Text format     Abstract available


  21. PARK YH, Lee SJ, Cho EY, La Choi Y, et al
    Clinical relevance of TNM staging system according to breast cancer subtypes.
    Ann Oncol. 2019;30:2011.
    PubMed     Text format    


  22. DUBSKY P, Montagna G, Ritter M
    Lymphocyte infiltration predicts survival in chemotherapy-naive, triple-negative breast cancer and identifies patients with intrinsically good prognosis: have we been bringing owls to Athens?
    Ann Oncol. 2019;30:1849-1850.
    PubMed     Text format    


    November 2019
  23. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2019;30:1842.
    PubMed     Text format    


  24. FERREIRA AR, Di Meglio A, Pistilli B, Gbenou AS, et al
    Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
    Ann Oncol. 2019;30:1784-1795.
    PubMed     Text format     Abstract available


  25. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Ann Oncol. 2019;30:1776-1783.
    PubMed     Text format     Abstract available


  26. BRANDAO M, Coens C, Ignatiadis M
    Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?
    Ann Oncol. 2019;30:1677-1681.
    PubMed     Text format    


    October 2019
  27. DUBSKY P, Montagna G, Ritter M
    Lymphocyte infiltration predicts survival in chemotherapy-naive, triple negative breast cancer, and identifies patients with intrinsically good prognosis: Have we been bringing owls to Athens?
    Ann Oncol. 2019 Oct 18. pii: 5593649. doi: 10.1093.
    PubMed     Text format    


  28. FERREIRA AR, Di Meglio A, Pistilli B, Gbenou AS, et al
    Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
    Ann Oncol. 2019 Oct 8. pii: 5583691. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019;30:1674.
    PubMed     Text format    


  30. BURSTEIN HJ, Curigliano G, Loibl S, Dubsky P, et al
    Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
    Ann Oncol. 2019;30:1541-1557.
    PubMed     Text format     Abstract available


  31. ARNEDOS M, Gligorov J
    St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients' overtreatment and breaking the bank?
    Ann Oncol. 2019;30:1533-1535.
    PubMed     Text format    


    August 2019
  32. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index and Prediction of Benefit from Extended Endocrine Therapy in Breast Cancer Patients Treated in the Adjuvant Tamoxifen - To Offer More? (aTTom) Trial.
    Ann Oncol. 2019 Aug 28. pii: 5555808. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. ARNEDOS M, Gligorov J
    St Gallen international consensus guidelines in early breast cancer: Experts to prevent patients' overtreatment and breaking the bank?
    Ann Oncol. 2019 Aug 27. pii: 5555359. doi: 10.1093.
    PubMed     Text format    


  34. PARK YH, Lee SJ, Cho EY, La Choi Y, et al
    Clinical relevance of TNM staging system according to breast cancer subtypes.
    Ann Oncol. 2019 Aug 13. pii: 5549411. doi: 10.1093.
    PubMed     Text format    


  35. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2019 Aug 13. pii: 5548997. doi: 10.1093.
    PubMed     Text format    


  36. SRINIVASALU VK, Susan A, Philip A, Jose WM, et al
    147P Clinical significance of BCL-2 with basal and non-basal triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543073. doi: 10.1093.
    PubMed     Text format    


  37. BURSTEIN HJ, Curigliano G, Loibl S, Dubsky P, et al
    Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.
    Ann Oncol. 2019 Aug 2. pii: 5543097. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. SRINIVASALU VK, Susan A, Jose WM, Philip A, et al
    41P Prognostic significance of BCL-2 expression in triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543072. doi: 10.1093.
    PubMed     Text format    


    July 2019
  39. LOI S
    The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine.
    Ann Oncol. 2019 Jul 9. pii: 5530161. doi: 10.1093.
    PubMed     Text format    


  40. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017".
    Ann Oncol. 2019;30:1181.
    PubMed     Text format    


  41. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab".
    Ann Oncol. 2019;30:1180.
    PubMed     Text format    


  42. CORTES J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, et al
    Corrections to "Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis".
    Ann Oncol. 2019;30:1179.
    PubMed     Text format    


  43. PASCUAL J, Turner NC
    Targeting the PI3-kinase pathway in triple-negative breast cancer.
    Ann Oncol. 2019;30:1051-1060.
    PubMed     Text format     Abstract available


  44. MATIKAS A, Foukakis T, Swain S, Bergh J, et al
    Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
    Ann Oncol. 2019;30:1044-1050.
    PubMed     Text format     Abstract available


  45. FOULKES WD, Polak P
    Journey's end: the quest for BRCA-like hereditary breast cancer genes is nearly over.
    Ann Oncol. 2019;30:1023-1025.
    PubMed     Text format    


    June 2019
  46. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jun 24. pii: 5522519. doi: 10.1093.
    PubMed     Text format    


  47. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jun 4. pii: 5499075. doi: 10.1093.
    PubMed     Text format    


    May 2019
  48. OLIVEIRA M, Saura C, Nuciforo P, Calvo I, et al
    FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
    Ann Oncol. 2019 May 30. pii: 5506637. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. LOIBL S, Untch M, Burchardi N, Huober J, et al
    A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.
    Ann Oncol. 2019 May 16. pii: 5490226. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. FOULKES WD, Polak P
    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.
    Ann Oncol. 2019 May 15. pii: 5489599. doi: 10.1093.
    PubMed     Text format    


  51. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    Reply to the Letter to the Editor: "European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al." by J. Marsden, H. Hamoda, On behalf of the British Menopause Society Medical Advisory Council.
    Ann Oncol. 2019 May 9. pii: 5487409. doi: 10.1093.
    PubMed     Text format    


  52. MARSDEN J, Hamoda H
    European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al. (Ann Oncol 2019; 30: doi.org/10.1093/annonc/mdz051).
    Ann Oncol. 2019 May 9. pii: 5482565. doi: 10.1093.
    PubMed     Text format    


  53. PASCUAL J, Turner NC
    Targeting the PI3-kinase pathway in triple negative breast cancer.
    Ann Oncol. 2019 May 3. pii: 5485241. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2019 with focus on breast cancer.
    Ann Oncol. 2019;30:781-787.
    PubMed     Text format     Abstract available


  55. TURNER NC, Alarcon E, Armstrong AC, Philco M, et al
    BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK
    Ann Oncol. 2019;30:774-780.
    PubMed     Text format     Abstract available


  56. BACHELOT T, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Ann Oncol. 2019;30:766-773.
    PubMed     Text format     Abstract available


    April 2019
  57. DE AZAMBUJA E, Piccart-Gebhart M
    ER+/HER2+ breast cancer: are we really de-escalating?
    Ann Oncol. 2019 Apr 16. pii: 5472336. doi: 10.1093.
    PubMed     Text format    


  58. MATIKAS A, Foukakis T, Swain S, Bergh J, et al
    Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
    Ann Oncol. 2019 Apr 9. pii: 5435960. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. MARRA A, Curigliano G
    T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer.
    Ann Oncol. 2019 Apr 2. pii: 5425459. doi: 10.1093.
    PubMed     Text format    


  60. DELALOGE S, Cella D, Ye Y, Buyse M, et al
    Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
    Ann Oncol. 2019;30:567-574.
    PubMed     Text format     Abstract available


  61. ROBSON ME, Tung N, Conte P, Im SA, et al
    OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Ann Oncol. 2019;30:558-566.
    PubMed     Text format     Abstract available


    March 2019
  62. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
    Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Ann Oncol. 2019 Mar 30. pii: 5423828. doi: 10.1093.
    PubMed     Text format    


  63. MESSAOUDENE M, Mourikis TP, Michels J, Fu Y, et al
    T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.
    Ann Oncol. 2019 Mar 29. pii: 5423181. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. VEERARAGHAVAN J, De Angelis C, Mao R, Wang T, et al
    A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
    Ann Oncol. 2019 Mar 23. pii: 5418530. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2019 with focus on breast cancer.
    Ann Oncol. 2019 Mar 19. pii: 5382368. doi: 10.1093.
    PubMed     Text format     Abstract available


  66. HREBIEN S, Citi V, Garcia-Murillas I, Cutts R, et al
    Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.
    Ann Oncol. 2019 Mar 12. pii: 5376514. doi: 10.1093.
    PubMed     Text format     Abstract available


  67. TURNER NC, Alarcon E, Armstrong AC, Philco M, et al
    BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK
    Ann Oncol. 2019 Mar 12. pii: 5376517. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  68. BACHELOT T, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Ann Oncol. 2019 Feb 23. pii: 5364015. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. GUARNERI V, Dieci MV, Bisagni G, Frassoldati A, et al
    De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study.
    Ann Oncol. 2019 Feb 18. pii: 5332974. doi: 10.1093.
    PubMed     Text format     Abstract available


  70. TELLI ML, Vinayak S
    Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way.
    Ann Oncol. 2019 Feb 7. pii: 5308591. doi: 10.1093.
    PubMed     Text format    


  71. YAP YS, Ho D, Ng RC, Chan CH, et al
    27PDetection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  72. SON S, Kim H, Shin I
    23PMatricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  73. KIM H, Son S
    22PTherapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  74. LUEN SJ, Salgado R, Dieci MV, Vingiani A, et al
    Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Ann Oncol. 2019;30:236-242.
    PubMed     Text format     Abstract available


  75. KIM H, Son S
    Therapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    PubMed     Text format    


  76. SON S, Kim H, Shin I
    Matricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    PubMed     Text format    


  77. YAP YS, Ho D, Ng RC, Chan CH, et al
    Detection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens.
    Ann Oncol. 2019;30 Suppl 1:i10.
    PubMed     Text format    


    January 2019
  78. CONDORELLI R, Mosele F, Verret B, Bachelot T, et al
    Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Ann Oncol. 2019 Jan 31. pii: 5305018. doi: 10.1093.
    PubMed     Text format     Abstract available


  79. ROBSON ME, Tung N, Conte P, Im SA, et al
    OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Ann Oncol. 2019 Jan 23. pii: 5299440. doi: 10.1093.
    PubMed     Text format     Abstract available


  80. DELALOGE S, Cella D, Ye Y, Buyse M, et al
    Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial.
    Ann Oncol. 2019 Jan 23. pii: 5299438. doi: 10.1093.
    PubMed     Text format     Abstract available


  81. DIECI MV, Conte P, Bisagni G, Brandes AA, et al
    Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
    Ann Oncol. 2019 Jan 17. pii: 5290085. doi: 10.1093.
    PubMed     Text format     Abstract available


  82. CORTES J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, et al
    Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
    Ann Oncol. 2019 Jan 9. pii: 5281258. doi: 10.1093.
    PubMed     Text format    


  83. BASELGA J, Manikhas A, Cortes J, Llombart A, et al
    Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281256. doi: 10.1093.
    PubMed     Text format    


  84. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281259. doi: 10.1093.
    PubMed     Text format    


  85. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281263. doi: 10.1093.
    PubMed     Text format    


  86. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2019 Jan 9. pii: 5281261. doi: 10.1093.
    PubMed     Text format    


  87. WU Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, et al
    Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281255. doi: 10.1093.
    PubMed     Text format    


    December 2018
  88. LUEN SJ, Salgado R, Dieci MV, Vingiani A, et al
    Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy.
    Ann Oncol. 2018 Dec 27. pii: 5262220. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2018
  89. ADAMS S, Schmid P, Rugo HS, Winer EP, et al
    Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209693. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. ADAMS S, Loi S, Toppmeyer D, Cescon DW, et al
    Title: Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209695. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. EVRON E, Ben-David AM, Goldberg H, Fried G, et al
    Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers with Early Stage Breast Cancer.
    Ann Oncol. 2018 Nov 23. pii: 5200725. doi: 10.1093.
    PubMed     Text format     Abstract available


  92. SOKOL ES, Feng YX, Jin DX, Basudan A, et al
    Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Ann Oncol. 2018 Nov 13. pii: 5181087. doi: 10.1093.
    PubMed     Text format     Abstract available


  93. FOUKAKIS T
    Carboplatin in the neoadjuvant treatment of triple-negative breast cancer - ready for prime time?
    Ann Oncol. 2018 Nov 5. pii: 5160131. doi: 10.1093.
    PubMed     Text format    


    October 2018
  94. MATHEW A, Erqou S
    Can Estrogen Receptor Status Predict for Shorter Duration of Adjuvant Trastuzumab in Early-Stage Breast Cancer?
    Ann Oncol. 2018 Oct 24. pii: 5144112. doi: 10.1093.
    PubMed     Text format    


  95. MATIKAS A, Foukakis T, Moebus V, Greil R, et al
    Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients.
    Ann Oncol. 2018 Oct 24. pii: 5144113. doi: 10.1093.
    PubMed     Text format     Abstract available


  96. KOK M, Winer E, Loi S
    Passion for Immune checkpoint blockade in triple negative breast cancer? Comment on the IMpassion130 study.
    Ann Oncol. 2018 Oct 23. pii: 5142540. doi: 10.1093.
    PubMed     Text format    


  97. COTTU P, D'Hondt V, Dureau S, Lerebours F, et al
    Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
    Ann Oncol. 2018 Oct 11. pii: 5126820. doi: 10.1093.
    PubMed     Text format     Abstract available


  98. BRANDAO M, Ignatiadis M
    CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?
    Ann Oncol. 2018 Oct 10. pii: 5126228. doi: 10.1093.
    PubMed     Text format    


    September 2018
  99. SZEKELY B, Bossuyt V, Li X, Wali VB, et al
    Immunological differences between primary and metastatic breast cancer.
    Ann Oncol. 2018 Sep 10. pii: 5094494. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  100. CHEN X, Li Y, Ouyang T, Li J, et al
    Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
    Ann Oncol. 2018 Aug 27. pii: 5079839. doi: 10.1093.
    PubMed     Text format     Abstract available


  101. ETTL J, Quek RGW, Lee KH, Rugo HS, et al
    Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    Ann Oncol. 2018 Aug 15. pii: 5074207. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  102. CARDOSO F, Senkus E, Costa A, Papadopoulos E, et al
    4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
    Ann Oncol. 2018 Jul 19. pii: 5055519. doi: 10.1093.
    PubMed     Text format    


  103. ROBSON M
    Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven't found what we're looking for.
    Ann Oncol. 2018 Jul 4. pii: 5048958. doi: 10.1093.
    PubMed     Text format    


    June 2018
  104. BRUSSELAERS N, Tamimi RM, Konings P, Rosner B, et al
    Different menopausal hormone regimens and risk of breast cancer.
    Ann Oncol. 2018 Jun 18. pii: 5039890. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
    Breast cancer brain metastases show increased levels of genomic aberration based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Ann Oncol. 2018 Jun 18. pii: 5039891. doi: 10.1093.
    PubMed     Text format     Abstract available


  106. ZHANG J, Lin Y, Sun XJ, Wang BY, et al
    Biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Ann Oncol. 2018 Jun 14. pii: 5037891. doi: 10.1093.
    PubMed     Text format     Abstract available


  107. IGNATIADIS M, Litiere S, Rothe F, Riethdorf S, et al
    Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.
    Ann Oncol. 2018 Jun 11. pii: 5035683. doi: 10.1093.
    PubMed     Text format     Abstract available


  108. MALORNI L, Curigliano G, Minisini AM, Cinieri S, et al
    Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
    Ann Oncol. 2018 Jun 11. pii: 5035682. doi: 10.1093.
    PubMed     Text format     Abstract available


  109. YARDLEY DA, Coleman R, Conte P, Cortes J, et al
    nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial.
    Ann Oncol. 2018 Jun 6. pii: 5033593. doi: 10.1093.
    PubMed     Text format     Abstract available


  110. POGGIO F, Bruzzone M, Ceppi M, Ponde NF, et al
    Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Ann Oncol. 2018 Jun 4. pii: 5026316. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  111. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2018 May 3. pii: 4992289. doi: 10.1093.
    PubMed     Text format    


  112. GAGE MM, Mylander WC, Rosman M, Fujii T, et al
    Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
    Ann Oncol. 2018;29:1280-1285.
    PubMed     Text format     Abstract available


  113. LIU C, Wang L, Zhuang J, Liu L, et al
    Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
    Ann Oncol. 2018;29:1329-1330.
    PubMed     Text format    


    April 2018
  114. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2018 Apr 27. pii: 4989216. doi: 10.1093.
    PubMed     Text format     Abstract available


  115. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2018 Apr 26. pii: 4986930. doi: 10.1093.
    PubMed     Text format    


  116. GEFFEN DB
    Should decisions on adding adjuvant chemotherapy in early stage ER positive breast cancer be based on gene expression testing or clinicopathologic factors or both?
    Ann Oncol. 2018 Apr 4. pii: 4959909. doi: 10.1093.
    PubMed     Text format    


  117. CRUZ C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, et al
    RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.
    Ann Oncol. 2018 Apr 4. pii: 4959904. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  118. CORTES J, Perez-Garcia J, Levy C, Gomez Pardo P, et al
    Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
    Ann Oncol. 2018 Feb 21. pii: 4897992. doi: 10.1093.
    PubMed     Text format     Abstract available


  119. MARTIN M, Campone M, Bondarenko I, Sakaeva D, et al
    Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Ann Oncol. 2018 Feb 10. pii: 4852792. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  120. TAN WW, Hillman DW, Salim M, Northfelt DW, et al
    N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
    Ann Oncol. 2018 Jan 29. pii: 4829660. doi: 10.1093.
    PubMed     Text format    


  121. BARECHE Y, Venet D, Ignatiadis M, Aftimos P, et al
    Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Ann Oncol. 2018 Jan 22. pii: 4819112. doi: 10.1093.
    PubMed     Text format     Abstract available


  122. HARTMAIER RJ, Trabucco SE, Priedigkeit N, Chung JH, et al
    Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer.
    Ann Oncol. 2018 Jan 19. pii: 4817340. doi: 10.1093.
    PubMed     Text format     Abstract available


  123. ABBOSH C, Swanton C, Birkbak NJ
    Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
    Ann Oncol. 2018 Jan 17. pii: 4815740. doi: 10.1093.
    PubMed     Text format    


  124. TURNER NC, Finn RS, Martin M, Im SA, et al
    Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases.
    Ann Oncol. 2018 Jan 11. pii: 4802189. doi: 10.1093.
    PubMed     Text format     Abstract available


  125. SOMASHEKHAR SP, Sepulveda MJ, Puglielli S, Norden AD, et al
    Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.
    Ann Oncol. 2018 Jan 9. pii: 4781689. doi: 10.1093.
    PubMed     Text format     Abstract available


  126. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2018 Jan 2. pii: 4782676. doi: 10.1093.
    PubMed     Text format    


    December 2017
  127. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Text format     Abstract available


  128. SHARMA P, Barlow WE, Godwin AK, Pathak H, et al
    Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313).
    Ann Oncol. 2017 Dec 23. pii: 4774220. doi: 10.1093.
    PubMed     Text format     Abstract available


  129. SWAIN SM, Ewer MS, Viale G, Delaloge S, et al
    Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
    Ann Oncol. 2017 Dec 15. pii: 4748818. doi: 10.1093.
    PubMed     Text format     Abstract available


  130. CONDORELLI R, Spring L, O'Shaughnessy J, Lacroix L, et al
    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
    Ann Oncol. 2017 Dec 11. pii: 4725051. doi: 10.1093.
    PubMed     Text format     Abstract available


  131. GENNARI A, Sun Z, Hasler-Strub U, Colleoni M, et al
    A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
    Ann Oncol. 2017 Dec 8. pii: 4710349. doi: 10.1093.
    PubMed     Text format     Abstract available


  132. PALUCH-SHIMON S, Peccatori FA
    BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients.
    Ann Oncol. 2017 Dec 5. pii: 4693825. doi: 10.1093.
    PubMed     Text format    


    November 2017
  133. FRANCIS PA
    Male Breast Cancer: Pink Ribbon Blues.
    Ann Oncol. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format    


  134. BUISSERET L, Pommey S, Allard B, Garaud S, et al
    Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  135. SESTAK I, Smith SG, Howell A, Forbes JF, et al
    Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
    Ann Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  136. PATEL R, Maxwell S, Yan D, Dressler EV, et al
    Medical Oncologists' Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women with Hormone Receptor-Positive Early Breast Cancer.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format    


    October 2017
  137. KOK M
    LAG-3: another brake to release in breast cancer?
    Ann Oncol. 2017 Oct 30. doi: 10.1093.
    PubMed     Text format    


  138. CARDOSO F, Bartlett JMS, Slaets L, van Deurzen CHM, et al
    Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  139. BLACKWELL K, Gascon P, Krendyukov A, Gattu S, et al
    Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase 3, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppr
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  140. CRISCITIELLO C, Bayar MA, Curigliano G, Symmans FW, et al
    A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer.
    Ann Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  141. MOBUS V, Jackisch C, Lueck HJ, du Bois A, et al
    Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial.
    Ann Oncol. 2017 Oct 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  142. NUCIFORO P, Pascual T, Cortes J, Llombart-Cussac A, et al
    A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Ann Oncol. 2017 Oct 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  143. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  144. LAMBERTINI M, Goldrat O, Ferreira AR, Dechene J, et al
    Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  145. FRIBBENS C, Garcia Murillas I, Beaney M, Hrebien S, et al
    Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
    Ann Oncol. 2017 Oct 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  146. FUJII T, Kogawa T, Dong W, Sahin AA, et al
    Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.
    Ann Oncol. 2017;28:2420-2428.
    PubMed     Text format     Abstract available


    September 2017
  147. HAN HS, Dieras V, Robson M, Palacova M, et al
    Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  148. BURUGU S, Gao D, Leung S, Chia SK, et al
    LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  149. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format    


  150. KIROVA YM, Carroll S, Fourquet A, Offersen B, et al
    The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology.
    Ann Oncol. 2017 Sep 22. doi: 10.1093.
    PubMed     Text format    


  151. CHAJES V, Assi N, Biessy C, Ferrari P, et al
    A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  152. MESSINA C, Messina M, Zanardi E
    Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  153. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
    Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  154. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+/HR- phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekl
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  155. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Text format     Abstract available


  156. HAMY AS, Pierga JY, Sabaila A, Laas E, et al
    Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
    Ann Oncol. 2017;28:2233-2240.
    PubMed     Text format     Abstract available


  157. BERNICHON E, Vallard A, Wang Q, Attignon V, et al
    Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
    Ann Oncol. 2017 Sep 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  158. VAN BOCKSTAL M, Libbrecht L, Floris G, Lambein K, et al
    Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?
    Ann Oncol. 2017;28:2317.
    PubMed     Text format    


    August 2017
  159. CHUNG JH, Pavlick D, Hartmaier R, Schrock AB, et al
    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Ann Oncol. 2017 Aug 31. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  160. PRUNERI G, Lazzeroni M, Bagnardi V, Tiburzio GB, et al
    The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Ann Oncol. 2017;28:321-328.
    PubMed     Text format     Abstract available


  161. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Text format     Abstract available


  162. MAKKOUK A, Sundaram V, Chester C, Chang S, et al
    Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.
    Ann Oncol. 2017;28:415-420.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: